Inhibition of colon cancer cell growth by dietary components: Role of the insulin-like growth factor (IGF) system

Asia Pacific Journal of Clinical Nutrition

Volumn 17, Issue SUPPL. 1, 2008, Pages 257-260

  Park, Jung Han Yoon ^a  

^a Hallym University   (South Korea)

Author keywords

Conjugated linoleic acid; IGF I receptor; IGFBPs; N 3 fatty acids; Retinoic acid; Vitamin D

Indexed keywords

SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ANIMAL; COLORECTAL TUMOR; DIET; HUMAN; INCIDENCE; LIFESTYLE; METABOLISM; REVIEW;

ANIMALS; COLORECTAL NEOPLASMS; DIET; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LIFE STYLE;

EID: 46049107415     PISSN: 09647058     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Hassan AB, Macaulay VM. The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol. 2002;13:349-56.
2. Singh P, Rubin N. Insulin-like growth factors and binding proteins in colon cancer. Gastroenterology. 1993;105:1218-37.
3. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Foundation symposium. 2004;262:247-60; discussion 260-8.
4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev. 1995;16:3-34.
5. Dupont J, LeRoith D. Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Horm Res. 2001;55 Suppl 2:22-6.
6. Hwa V, Oh Y, Rosenfeld, RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20:761-87.
7. Martin JL. IGFBPs down under. Trends Endocrinol Metab. 2001;12:142-4.
8. Ma J, Pollak MN, Giovannucci, E, Chan, JM, Tao, Y, Hennekens, CH, Stampfer, MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620-5.
9. Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, Riboli E, Kaaks R. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 2002;50:642-6.
10. DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson, B, Le Marchand, L. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev. 2004;13:1444-51.
11. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. Gene expression profiles in normal and cancer cells. Science. 1997;276:1268-72.
12. Winkler R, Delacroix L, Bensbaho K, Lambert S, Collette J, Hodzic D. IGF-II in primary human colorectal tumors: peptide level, activated promoters, parental imprinting and gene rearrangement. Horm Metab Res. 1999;31:148-54.
13. Miraki-Moud F, Jenkins PJ, Fairclough PD, Jordan S, Bustin SA, Jones AM, Lowe DG, Monson JP, Grossman AB, Besser GM, Camacho-Hubner C. Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly. Clin Endocrinol (Oxf). 2001;54:499-508.
14. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62:1030-5.
15. Zhang Y, Wick DA, Seetharam B, Dahms NM. Expression of IGF-II and IGF binding proteins in differentiating human intestinal Caco-2 cells. Am J Physiol. 1995;269 (Endocrinol Metabol 32):E804-13.
16. Park JH, Corkins MR, Vanderhoof JA, Caruso NM, Hrbek MJ, Schaffer BS, Slentz DH, McCusker RH, MacDonald RG. Expression of insulin-like growth factor-II and insulin-like growth factor binding proteins during Caco-2 cell proliferation and differentiation. J Cell Physiol. 1996;166:396-406.
17. Narayanan BA, Re GG. IGF-II down regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid. Anticancer Res. 2001;21:359-64.
18. Guo YS, Jin GF, Townsend CM, Zhang T, Sheng HM, Beauchamp RD, Thompson JC. Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions. J Am Coll Surg. 1995;181:145-54.
19. Oh YS, Kim EJ, Schaffer BS, Kang YH, Binderup L, MacDonald RG, Park JH. Synthetic low-calcaemic vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol. 2001;183:141-9.
20. Zarrilli RZ, Romano M, Pignata S, Casola S, Bruni CB, Acquaviva AM. Constitutive insulin-like growth factor-II expression interferes with the enterocyte-like differentiation of Caco-2 cells. J Biol Chem. 1996;271:8108-14.
21. Remacle-Bonnet M, Garrouste F, el Atique F, Marvaldi J, Pommier G. Cell polarity of the insulin-like growth factor system in human intestinal epithelial cells. Unique apical sorting of insulin-like growth factor binding protein-4 in differentiated human colon cancer cells. J Clin Invest. 1995;96:192-200.
22. Lamonerie T, Lavialle C, Haddada H, Brison O. IGF-2 autocrine stimulation in tumorigenic clones of a human colon-carcinoma cell line. Int J Cancer. 1995;61:587-92.
23. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, Acquaviva AM, Zarrilli R. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene. 2000;19:5517-24.
24. Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL, Carbone DP. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology. 2002;123:1191-204.
25. MacDonald RG, Schaffer BS, Kang IJ, Hong SM, Kim EJ, Park JH. Growth inhibition and differentiation of the human colon carcinoma cell line, Caco-2, by constitutive expression of insulin-like growth factor binding protein-3. J Gastroenterol Hepatol. 1999;14:72-8.
26. Park JHY. Growth stimuation and inhibition of differentiation of the human colon carcinoma cell line Caco-2 with an anti-sense insulin-like growth factor binding protein-3 construct. J Biochem Mol Biol. 1999;32:266-72.
27. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, Paraskeva C. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res. 2000;60:22-7.
28. Kirman I, Poltoratskaia N, Sylla P, Whelan RL. Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. Surgery. 2004;136:205-9.
29. Roynette CE, Calder PC, Dupertuis YM, Pichard C. n-3 polyunsaturated fatty acids and colon cancer prevention. Clin Nutr. 2004;23:139-51.
30. Kim EJ, Kim WY, Kang YH, Ha YL, Bach L, Park JHY. inhibition of Caco-2 cell proliferation by (n-3) fatty acids: possible mediation by increased secretion of insulin-like growth factor binding protein-6. Nutr Res. 2000;20:1409-21.
31. Hong WK, Itri LM. Retinoids and human cancer. in The Retinoids (eds. Sporn MB, Roberts AB & Goodman, D.S.) 597-630 (Raven Press, New York, 1994).
32. Kim EJ, Schaffer BS, Kang Y-H, Macdonald RG, Park JHY. Decreased production of insulin-like growth factor binding protein (IGFBP)-6 by transfection of colon cancer cells with an antisense IGFBP-6 cDNAconstruct leads to stimulation of cell proliferation. J Gastroenterol Hepatol. 2002;17:563-70.
33. Kim EJ, Kang YH, Schaffer BS, Bach LA, MacDonald RG, Park JH. Inhibition of Caco-2 cell proliferation by all-trans retinoic acid: role of insulin-like growth factor binding protein-6. J Cell Physiol. 2002;190:92-100.
34. Bostick RM, Potter JD, Sellers TA, McKenzie DR, Kushi LH, Folsom AR. Relation of calcium, vitamin D, and daily food intake to incidence of colon cancer among older women. Am J Epidemiol. 1993;137:1302-17.
35. Bikle DD. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocrine Rev. 1992;13:765-84.
36. Feldman D, Zhao X-Y, Krishnan AV. Editorial/mini-review: vitamin D and prostate cancer. Endocrinology. 2000;141:5-9.
37. Belury MA. Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. J Nutr. 2002;132:2995-8.
38. Park HS, Ryu JH, Ha YL, Park JH. Dietary conjugated linoleic acid (CLA) induces apoptosis of colonic mucosa in 1,2-dimethylhydrazine-treated rats: a possible mechanism of the anticarcinogenic effect by CLA. Br J Nutr. 2001;86:549-55.
39. Soel SM, Choi OS, Bang MH, Yoon Park JH, Kim WK. Influence of conjugated linoleic acid isomers on the metastasis of colon cancer cells in vitro and in vivo. J Nutr Biochem. 2007;18:650-7.
40. Cho HJ, Kim WK, Kim EJ, Jung KC, Park S, Lee HS, Tyner AL, Park JH. Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. Am J Physiol Gastrointest Liver Physiol. 2003;284:G996-1005.
41. Kim EJ, Kang IJ, Cho HJ, Kim WK, Ha YL, Park JH. Conjugated linoleic acid downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. J Nutr. 2003;133:2675-81.
42. Kim EJ, Holthuizen PE, Park HS, Ha YL, Jung KC, Park JH. Trans-10,cis-12-conjugated linoleic acid inhibits Caco-2 colon cancer cell growth. Am J Physiol Gastrointest Liver Physiol. 2002;283:G357-67.
43. Cho HJ, Lee HS, Chung CK, Kang YH, Ha YL, Park HS, Park JH. trans-10, cis-12 conjugated linoleic acid reduces insulin-like growth factor-II secretion in HT-29 human colon cancer cells. J Med Food. 2003;6:193-9.